© crevis - stock.adobe.com

AVT03, a biosimilar candidate for osteoporosis treatment, showed promise in treating bone illnesses, according to results from a pharmacokinetic study by Alvotech SA.

© NicoElNino - stock.adobe.com

Danish Novozymes A/S and Chr. Hansen Holding A/S have completed their merger, creating a new company named Novonesis.

On 23 January, Belgian Agri-minister David Clarinval (background, right) met with his Polish colleague Czes?aw Siekierski (center) at the Agrifish Council for bilateral talks, © Consilium

Following the AGRI Committee of the European Parliament, the lead ENVI Committee has also agreed to relax the rules for the authorisation of NGTs.

Picture: ScandiNova Group

Uppsala-based ScandiNova Systems AB appoints Pernilla Enkler as the new Head of Sustainability, Quality and Communication – a newly established division.

© Calluna Pharma, edited by BIOCOM

Forbion has spearheaded a €75m Series A financing in Norwegian biotech Calluna Pharma. The clinical-stage company resulted from the merger of Oxitope Pharma and Arxx Therapeutics.

AC Immune at the EPFL Innovation Park © AC Immune

Genentech, Roche’s US subsidiary, is ending its decades-long collaboration with AC Immune SA after disappointing study results. It has handed the global rights to Crenezumab and Semorinemab back to the Lausanne-based biotech.

Janusz Wojciechowski, European Commissioner for Agriculture from Poland, and David Clarinval, Belgian Minister of Agriculture at the AGRI Council in November 2023 © UE

After the EU Parliament’s Agriculture (AGRI) Committee called for a patent ban on NGT-1 breeds on 8 January, the ENVI Committee will give its input to the EU Commissions draft law on new genomic techniques.

AMsilk GmbH's headquarters in Neuried. The company, in which Novo holds a €29m equity stake,  has no manufacturing facility but works with contractors such as 21st.BIO. © AMSilk GmbH

AMSilk GmbH and Danish 21st.BIO A/S announce partnership to accelerate the production of advanced materials made from spider silk-based proteins.

Ruben de Francisco, Founder & CEO Onera Health. © Onera Health NV

Sleep diagnostics specialist Onera Health NV has closed a €30m (US$32m) Series C financing round co-led by EQT Life Sciences and Gimv.

Basilea headquarters in Alschil, Switzerland. © Mohamd Ghani - wikipedia.org

Macrocycle library secialist Spexis AG is set to sell a preclinical antibiotics programme afor CHF2m to Basilea Pharmaceutica Ltd.